Mandibular impacted third molar
Conditions
Interventions
Experimental group:Reduced anesthesia combined with taVNS stimulation
Control group:Conventional anesthesia combined with sham taVNS stimulation
Sponsors
The Second Affiliated Hospital of Yunnan University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-60 years; 2. Meets the indications for impacted third molar extraction according to the 8th edition of "Oral and Maxillofacial Surgery," requiring extraction of a unilateral mandibular impacted third molar; 3. Pell-Gregory classification: Class II ramus, Class B occlusal plane; 4. Winter classification: mesioangular impaction (angle with the long axis of the second molar 2mm, and the root morphology is single-rooted or fused root; 6. ASA classification I-II, normal coagulation function; 7. Signed informed consent, voluntarily participating in this study.
Exclusion criteria
Exclusion criteria: 1. Combined acute periodontal disease, temporomandibular joint disorder syndrome, or acute infection of the oral mucosa and maxillofacial region; 2. Systemic malignant diseases (such as hemophilia, leukemia, aplastic anemia) or oral malignant tumors; 3. Patients with organic cardiovascular diseases such as hypertension or heart disease; 4. Severe liver or kidney dysfunction; 5. History of lidocaine allergy or contraindications to the use of local anesthetics; 6. Local rash, infection, skin lesions, ulcers, or scars in the auricular region; 7. Patients with implanted stimulators (such as pacemakers, implanted vagus nerve stimulators, deep brain stimulators, or spinal cord stimulators), cochlear implants, or a history of metal implants; 8. Pregnant or breastfeeding women; 9. Patients with a clear history of neurological or psychiatric disorders or a history of corresponding medication use; 10. Patients who smoke, abuse alcohol, or are addicted to other substances; 11. Long-term use of anti-inflammatory drugs, analgesics, or drugs affecting the vagus nerve; 12. Patients with systemic autoimmune diseases or who have had an acute infection or major surgery within the past 4 weeks; 13. Currently participating in other studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraoperative pain VAS score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total Bureau Narcotics Usage;Intraoperative blood loss;Heart rate, blood pressure, respiratory rate, and blood oxygen saturation levels;Onset and duration of anesthesia;Blind assessment;Postoperative pain medication dosage;Incidence of adverse events;Postoperative pain VAS score;Postoperative complication rate;Anesthesia Satisfaction Score; | — |
Countries
China
Contacts
Public ContactTaipin Guo
The Second Affiliated Hospital of Yunnan University of Chinese Medicine
Outcome results
None listed